Alagille Syndrome (ALGS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Alagille syndrome (ALGS), identified by OMIM 118450, is an autosomal dominant disorder linked to Notch signaling pathway abnormalities. It affects various systems, including the liver, heart, skeleton, eyes, kidneys, and central nervous system, often exhibiting distinct facial features. Most cases (about 97%) stem from JAG1 gene haploinsufficiency on 20p11.2-20p12 (encoding JAGGED1), caused primarily by mutations or deletions. A smaller fraction (<1%) arises from NOTCH2 mutations, which may lead to more frequent renal malformations. New mutations (approximately 60%) are common, and germline mosaicism rates are relatively high. Key clinical features of ALGS encompass bile duct paucity in liver biopsy, cholestasis, congenital heart defects (mainly pulmonary artery involvement), butterfly vertebrae, ophthalmic anomalies (most commonly posterior embryotoxon), and distinct facial characteristics. Additional manifestations may include renal irregularities, growth failure, developmental delays, splenomegaly, and vascular issues. For individuals with an ALGS diagnosis, crucial assessments, if not already conducted during the diagnostic process, include:

 

1.       Evaluation by a pediatrician, physician, or gastroenterologist, incorporating liver function tests (with elevated GGT levels associated with ALGS-related conjugated hyperbilirubinemia), serum cholesterol and triglycerides, bile acid levels, clotting studies, liver ultrasound, scintiscan, and biopsy.

2.       Comprehensive cardiac assessment.

3.       AP spinal X-ray.

4.       Ophthalmic evaluation.

5.       Renal ultrasound and renal function tests.

FDA-approved medications for managing cholestatic pruritus associated with Alagille syndrome are Livmarli (maralixibat) and Bylvay (odevixibat). They inhibit the ileal bile acid transporter (IBAT) to reduce serum bile acid levels.

 

·       Alagille syndrome incidence has been estimated to be 2 to 3 cases in every 100,000 population.

 

Thelansis’s “Alagille Syndrome (ALGS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alagille Syndrome (ALGS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Alagille Syndrome (ALGS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Alagille Syndrome (ALGS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Alagille Syndrome (ALGS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Alagille Syndrome (ALGS), Alagille Syndrome (ALGS) market outlook, Alagille Syndrome (ALGS) competitive landscape, Alagille Syndrome (ALGS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)